79 related articles for article (PubMed ID: 20470222)
1. Polo-like kinase 1 is essential to DNA damage recovery.
Liu L; Zhang M; Zou P
Leuk Lymphoma; 2010 Jun; 51(6):1079-89. PubMed ID: 20470222
[TBL] [Abstract][Full Text] [Related]
2. Polo-like kinase 1 as a promising diagnostic biomarker and potential therapeutic target for hepatocellular carcinoma.
Yousef EH; El-Mesery ME; Habeeb MR; Eissa LA
Tumour Biol; 2020 Apr; 42(4):1010428320914475. PubMed ID: 32252611
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint adaptation and recovery: back with Polo after the break.
van Vugt MA; Medema RH
Cell Cycle; 2004 Nov; 3(11):1383-6. PubMed ID: 15492511
[TBL] [Abstract][Full Text] [Related]
4. The p53-inducible gene 3 (PIG3) contributes to early cellular response to DNA damage.
Lee JH; Kang Y; Khare V; Jin ZY; Kang MY; Yoon Y; Hyun JW; Chung MH; Cho SI; Jun JY; Chang IY; You HJ
Oncogene; 2010 Mar; 29(10):1431-50. PubMed ID: 20023697
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
6. Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition.
Kreis NN; Louwen F; Zimmer B; Yuan J
Oncotarget; 2015 Mar; 6(9):6611-26. PubMed ID: 25483104
[TBL] [Abstract][Full Text] [Related]
7. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.
Peter B; Gleixner KV; Cerny-Reiterer S; Herrmann H; Winter V; Hadzijusufovic E; Ferenc V; Schuch K; Mirkina I; Horny HP; Pickl WF; Müllauer L; Willmann M; Valent P
Haematologica; 2011 May; 96(5):672-80. PubMed ID: 21242189
[TBL] [Abstract][Full Text] [Related]
8. Promotion of mitosis by activated protein kinase B after DNA damage involves polo-like kinase 1 and checkpoint protein CHFR.
Shtivelman E
Mol Cancer Res; 2003 Nov; 1(13):959-69. PubMed ID: 14638868
[TBL] [Abstract][Full Text] [Related]
9. Pharmaceutically inhibiting polo-like kinase 1 exerts a broad anti-tumour activity in retinoblastoma cell lines.
Schwermer M; Dreesmann S; Eggert A; Althoff K; Steenpass L; Schramm A; Schulte JH; Temming P
Clin Exp Ophthalmol; 2017 Apr; 45(3):288-296. PubMed ID: 27647547
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer.
Wang ZX; Xue D; Liu ZL; Lu BB; Bian HB; Pan X; Yin YM
Int J Biochem Cell Biol; 2012 Jan; 44(1):200-10. PubMed ID: 22064247
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinases and DNA damage checkpoint: beyond the traditional mitotic functions.
Bahassi el M
Exp Biol Med (Maywood); 2011 Jun; 236(6):648-57. PubMed ID: 21558091
[TBL] [Abstract][Full Text] [Related]
12. Polo-like kinase 1 phosphorylation of G2 and S-phase-expressed 1 protein is essential for p53 inactivation during G2 checkpoint recovery.
Liu XS; Li H; Song B; Liu X
EMBO Rep; 2010 Aug; 11(8):626-32. PubMed ID: 20577264
[TBL] [Abstract][Full Text] [Related]
13. Genistein-induced neuronal apoptosis and G2/M cell cycle arrest is associated with MDC1 up-regulation and PLK1 down-regulation.
Ismail IA; Kang KS; Lee HA; Kim JW; Sohn YK
Eur J Pharmacol; 2007 Dec; 575(1-3):12-20. PubMed ID: 17706963
[TBL] [Abstract][Full Text] [Related]
14. DITMD-induced mitotic defects and apoptosis in tumor cells by blocking the polo-box domain-dependent functions of polo-like kinase 1.
Kim KU; Lee JH; Lee MY; Chae CH; Lee JH; Lee BH; Oh KS
Eur J Pharmacol; 2019 Mar; 847():113-122. PubMed ID: 30689997
[TBL] [Abstract][Full Text] [Related]
15. Polo-like kinase 1 inactivation following mitotic DNA damaging treatments is independent of ataxia telangiectasia mutated kinase.
Yuan JH; Feng Y; Fisher RH; Maloid S; Longo DL; Ferris DK
Mol Cancer Res; 2004 Jul; 2(7):417-26. PubMed ID: 15280449
[TBL] [Abstract][Full Text] [Related]
16. Polo-like Kinase Inhibitor Volasertib Exhibits Antitumor Activity and Synergy with Vincristine in Pediatric Malignancies.
Abbou S; Lanvers-Kaminsky C; Daudigeos-Dubus E; LE Dret L; Laplace-Builhe C; Molenaar J; Vassal G; Geoerger B;
Anticancer Res; 2016 Feb; 36(2):599-609. PubMed ID: 26851014
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase-1 phosphorylates MDM2 at Ser260 and stimulates MDM2-mediated p53 turnover.
Dias SS; Hogan C; Ochocka AM; Meek DW
FEBS Lett; 2009 Nov; 583(22):3543-8. PubMed ID: 19833129
[TBL] [Abstract][Full Text] [Related]
18. The forkhead-associated domain protein Cep170 interacts with Polo-like kinase 1 and serves as a marker for mature centrioles.
Guarguaglini G; Duncan PI; Stierhof YD; Holmström T; Duensing S; Nigg EA
Mol Biol Cell; 2005 Mar; 16(3):1095-107. PubMed ID: 15616186
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 downregulates the kinase activity of Polo-like kinase 1 in response to replication stress.
Zou J; Rezvani K; Wang H; Lee KS; Zhang D
Cell Cycle; 2013 Jul; 12(14):2255-65. PubMed ID: 24067368
[TBL] [Abstract][Full Text] [Related]
20. Normal cells, but not cancer cells, survive severe Plk1 depletion.
Liu X; Lei M; Erikson RL
Mol Cell Biol; 2006 Mar; 26(6):2093-108. PubMed ID: 16507989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
